Drug
BR96-Doxorubicin Immunoconjugate clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2000
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2000 (2)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2004 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BR96-Doxorubicin Immunoconjugate is read from its arms, and is right about nine times in ten.
Testing it · 5
- Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate CancerCompletedPhase 2Seagen Inc.NCT00031187Written as SGN-15 (cBR96-doxorubicin immunoconjugate)
- Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung CarcinomaCompletedPhase 2Seagen Inc.NCT00051571Written as SGN-15
- FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung CarcinomaCompletedPhase 2Seagen Inc.NCT00086333Written as SGN-15, Docetaxel
- Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian CancerTerminatedPhase 2Seagen Inc.NCT00051584Written as SGN-15 (cBR96-Doxorubicin Immunoconjugate)
- Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast CancerTerminatedPhase 2Seagen Inc.NCT00028483Written as cBR96-doxorubicin immunoconjugate